# Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections

> **NCT03426761** · PHASE4 · COMPLETED · sponsor: **Infectious Diseases Physicians, Inc.** · enrollment: 41 (actual)

## Conditions studied

- Bone Infection
- Osteomyelitis
- Septic Arthritis
- Joint Infection
- Prosthetic Joint Infection

## Interventions

- **DRUG:** Dalbavancin
- **DRUG:** Vancomycin

## Key facts

- **NCT ID:** NCT03426761
- **Lead sponsor:** Infectious Diseases Physicians, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-25
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2023-10-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03426761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03426761, "Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03426761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*